Video

Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Related Videos
Image of a man with short black hair.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Image of a man with white hair and a white goatee.
Image of a woman with brown wavy hair, wearing a navy blue top.
Image of a man wearing a suit with a red bowtie.